Clinical Trial

Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer

Study acronym: OPTIMAS
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate intermittent relugolix + androgen receptor pathway inhibitor (ARPI) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) achieving optimal PSA response.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-10-08; most recent amendment 2026-06-18.
Status change: Not Yet Recruiting → Recruiting 2025-10-27
Trial Details
NCT Number NCT07216248
Lead Sponsor University of Utah
Conditions Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Enrollment 160 participants
Start Date 2025-10-27
Primary Completion 2030-10 (estimated)
Study Completion 2031-10 (estimated)
Updated on ClinicalTrials.gov 2026-06-23